1. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Issue 5 (1998) Authors: Robak, T.; Gladalska, A.; Stepień, H.; Robak, E. Journal: Mediators of inflammation Issue: Volume 7:Issue 5(1998) Page Start: 347 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT‐NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA. (12th June 2019) Authors: Wang, M.; Belada, D.; Cheah, C.; Chu, M.P.; Dreyling, M.; Flinn, I.; Fogliatto, L.; Goy, A.; Inwards, D.; Jurczak, W.; Mayer, J.; Re, F.; Robak, T.; Spurgeon, S.; Yoon, S.S.; Zinzani, P.L.; Yin, M.; Chen, T.; Kahl, B. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 554 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FIVE‐YEAR FOLLOW‐UP OF FIRST‐LINE IBRUTINIB FOR TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA//SMALL LYMPHOCYTIC LYMPHOMA. (12th June 2019) Authors: Tedeschi, A.; Burger, J.; Barr, P.M.; Robak, T.; Owen, C.; Ghia, P.; Bairey, O.; Hillmen, P.; Coutre, S.; Devereux, S.; Grosicki, S.; McCarthy, H.; Li, J.; Simpson, D.; Offner, F.; Moreno, C.; Dai, S.; Lal, I.; Dean, J.P.; Kipps, T.J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (12th August 2015) Authors: Robak, T.; Matutes, E.; Catovsky, D.; Zinzani, P. L.; Buske, C. Journal: Annals of oncology Issue: Volume 26(2015)Supplement 5 Page Start: v100 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY. (17th June 2021) Authors: Wang, M.; Rule, S.; Zinzani, P. L.; Goy, A.; Casasnovas, O.; Smith, S. D.; Damaj, G.; Doorduijn, J. K.; Lamy, T.; Morschhauser, F.; Panizo, C.; Shah, B.; Davies, A.; Eek, R.; Dupuis, J.; Jacobsen, E.; Kater, A. P.; Le Gouill, S.; Oberic, L.; Robak, T. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 7‐YEAR RESULTS FROM RESONATE‐2. (17th June 2021) Authors: Coutre, S. E.; Barr, P. M.; Owen, C.; Robak, T.; Tedeschi, A.; Bairey, O.; Burger, J. A.; Hillmen, P.; Devereux, S.; Grosicki, S.; McCarthy, H.; Li, J.; Simpson, D.; Offner, F.; Moreno, C.; Dai, S.; Szoke, A.; Dean, J. P.; Kipps, T. J.; Ghia, P. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P868: A CIRCULATING SERUM MIRNAS-BASED MODEL TO PREDICT EARLY MORTALITY IN MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-BASED REGIMENS. (23rd June 2022) Authors: Puła, A.; Robak, P.; Jarych, D.; Mikulski, D.; Dróżdż, I.; Szemraj, J.; Robak, T. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 761 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P1131: POST HOC ANALYSIS OF PATIENTS WITH HIGHLY PROLIFERATIVE VARIANTS OF MANTLE CELL LYMPHOMA TREATED WITH ACALABRUTINIB. (23rd June 2022) Authors: Le Gouill, S.; Długosz-Danecka, M.; Rule, S.; Luigi Zinzani, P.; Goy, A.; Smith, S. D.; Doorduijn, J. K.; Panizo, C.; Shah, B.; Davies, A.; Eek, R.; Jacobsen, E.; Kater, A. P.; Robak, T.; Jain, P.; Calvo, R.; Yang, H.; Wang, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1021 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. S175: ATLAS: A PHASE 3 RANDOMIZED TRIAL OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE ALONE AFTER STEM-CELL TRANSPLANT FOR MULTIPLE MYELOMA. (23rd June 2022) Authors: Dytfeld, D.; Wróbel, T.; Jamroziak, K.; Kubicki, T.; Robak, P.; Walter-Croneck, A.; Czyż, J.; Tyczyńska, A.; Druzd-Sitek, A.; Giannopoulos, K.; Nowicki, A.; Szczepaniak, T.; Łojko-Dankowska, A.; Matuszak, M.; Gil, L.; Puła, B.; Rybka, J.; Majcherek, M.; Usnarska-Zubkiewicz, L.; Szukalski, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P662: PATIENT-REPORTED OUTCOMES FROM A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VERSUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN PATIENTS WITH TREATMENT-NAÏVE (TN) CLL/SLL. (23rd June 2022) Authors: Ghia, P.; Barnes, G.; Yang, K.; Tam, C.; Hillmen, P.; Robak, T.; Brown, J.; Kahl, B.; Tian, T.; Szeto, A.; Paik, J.; Shadman, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 560 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗